Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma

被引:15
作者
Fan, Weiqiang [1 ]
Ma, Huan [1 ]
Jin, Bin [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Organ Transplantat, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China
关键词
forkhead box protein M1; polo-like kinase 1; hepatocellular carcinoma; cell cycle; M1 TRANSCRIPTION FACTOR; POLO-LIKE KINASES; POOR-PROGNOSIS; CLINICOPATHOLOGICAL FEATURES; IMMUNE LANDSCAPE; INHIBITOR; CELLS; PHOSPHORYLATION; OVEREXPRESSION; BEVACIZUMAB;
D O I
10.3892/ol.2022.13266
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma (HCC) is one of the most frequently encountered malignant tumor types and to improve its treatment, effective prognostic biomarkers are urgently required. Cell cycle dysregulation is a significant feature of cancer progression. The aim of the present study was to estimate the expression levels of forkhead box protein M1 (FOXM1) and polo-like kinase 1 (PLK1), both of which have essential roles in cell cycle regulation, and determine their prognostic value in HCC. To this end, FOXM1 and PLK1 expression levels were assessed in The Cancer Genome Atlas and International Cancer Genome Consortium Japan HCC cohorts, and the associations between their co-expression were determined via Pearson's correlation analysis. Furthermore, the overall survival and disease-free survival in these cohorts for different FOXM1 and PLK1 expression statuses were analyzed. In vitro knockdown experiments were also performed using Huh7 cells. The results obtained indicated overexpression of FOXM1 and PLK1 in HCC tumor tissues as well as a positive correlation between FOXM1 and PLK1 expression. The results also suggested that both FOXM1 and PLK1 are required for HCC cell proliferation. In addition, upregulation of FOXM1 and PLK1 was indicated to be associated with poor prognosis of patients with HCC. However, only their coordinated overexpression was identified as an independent prognostic factor for HCC.
引用
收藏
页数:12
相关论文
共 56 条
[1]   Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets [J].
Agarwal, Rahul ;
Narayan, Jitendra ;
Bhattacharyya, Amitava ;
Saraswat, Mayank ;
Tomar, Anil Kumar .
CANCER GENETICS, 2017, 216 :37-51
[2]   Polo-like kinases and the orchestration of cell division [J].
Barr, FA ;
Silljé, HHW ;
Nigg, EA .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (06) :429-440
[3]   Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications [J].
Cariani, Elisabetta ;
Missale, Gabriele .
LIVER INTERNATIONAL, 2019, 39 (09) :1608-1621
[4]   FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1 [J].
Chai, Na ;
Xie, Hua-hong ;
Yin, Ji-peng ;
Sa, Ke-di ;
Guo, Yi ;
Wang, Meng ;
Liu, Jun ;
Zhang, Xiao-fang ;
Zhang, Xiang ;
Yin, Hong ;
Nie, Yong-zhan ;
Wu, Kai-chun ;
Yang, An-gang ;
Zhang, Rui .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 500 (04) :924-929
[5]   A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1 [J].
Chen, Yi-Ju ;
Dominguez-Brauer, Carmen ;
Wang, Zebin ;
Asara, John M. ;
Costa, Robert H. ;
Tyner, Angela L. ;
Lau, Lester F. ;
Raychaudhuri, Pradip .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (44) :30695-30707
[6]   Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma [J].
Cheng, Li ;
Wang, Chongchong ;
Jing, Juehua .
CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (10) :1347-1350
[7]   Regulating a key mitotic regulator, polo-like kinase 1 (PLK1) [J].
Colicino, Erica G. ;
Hehnly, Heidi .
CYTOSKELETON, 2018, 75 (11) :481-494
[8]   Playing polo during mitosis: PLK1 takes the lead [J].
Combes, G. ;
Alharbi, I. ;
Braga, L. G. ;
Elowe, S. .
ONCOGENE, 2017, 36 (34) :4819-4827
[9]   FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas [J].
Dibb M. ;
Han N. ;
Choudhury J. ;
Hayes S. ;
Valentine H. ;
West C. ;
Sharrocks A.D. ;
Ang Y.S. .
BMC Research Notes, 8 (1)
[10]   Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma [J].
Duffy, Austin G. ;
Ulahannan, Susanna V. ;
Makorova-Rusher, Oxana ;
Rahma, Osama ;
Wedemeyer, Heiner ;
Pratt, Drew ;
Davis, Jeremy L. ;
Hughes, Marybeth S. ;
Heller, Theo ;
ElGindi, Mei ;
Uppala, Ashish ;
Korangy, Firouzeh ;
Kleiner, David E. ;
Figg, William D. ;
Venzon, David ;
Steinberg, Seth M. ;
Venkatesan, Aradhana M. ;
Krishnasamy, Venkatesh ;
Abi-Jaoudeh, Nadine ;
Levy, Elliot ;
Wood, Brad J. ;
Greten, Tim F. .
JOURNAL OF HEPATOLOGY, 2017, 66 (03) :545-551